Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 21;17(14):2380.
doi: 10.3390/nu17142380.

Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients

Affiliations
Review

Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients

Saniya Khan et al. Nutrients. .

Abstract

Polycystic liver disease (PLD) is a rare genetic disorder characterized by the development of >10 fluid-filled cysts in the liver. While PLD can occur in isolation, it is most commonly associated with autosomal dominant polycystic kidney disease, adding complexity to its management. PLD is often asymptomatic but can lead to hepatomegaly, causing symptoms such as abdominal distension, pain and discomfort, early satiety, gastroesophageal reflux, and malnutrition, ultimately affecting patients' quality of life. Current treatment strategies, including pharmacological and interventional approaches, focus on reducing liver volume and alleviating symptoms. However, management remains largely symptomatic, as no definitive therapies exist to halt cyst progression. Liver transplantation is the only curative option for patients with severe, progressive disease and refractory complications. The EASL guidelines recognize that PLD-related symptoms, primarily due to hepatomegaly, can contribute to involuntary weight loss and recommend assessing symptomatic patients for malnutrition and sarcopenia. Although evidence suggests that patients with PLD may be at risk of malnutrition, original data on the quality and extent of nutritional alterations remain scarce. The potential influence of nutrition on disease progression, symptom burden, and overall well-being is also largely unexplored. Given these knowledge gaps, addressing nutritional challenges, such as early satiety, is essential for optimizing symptom management and maintaining overall nutritional status. This review outlines a possible pathophysiology of malnutrition, specific dietary considerations and recommendations, and weight management in patients with PLD. Additionally, dietary complexities in patients with concurrent renal involvement are discussed, offering a practical framework for clinicians and dietitians in managing this challenging condition.

Keywords: malnutrition; nutrition; polycystic liver disease; quality of life; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Proposed pathophysiology of malnutrition in polycystic liver disease (PLD).

Similar articles

  • Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement.
    Cheng AL, Herman E, Abramoff B, Anderson JR, Azola A, Baratta JM, Bartels MN, Bhavaraju-Sanka R, Blitshteyn S, Fine JS, Fleming TK, Verduzco-Gutierrez M, Herrera JE, Karnik R, Kurylo M, Longo MT, McCauley MD, Melamed E, Miglis MG, Neal JD, Oleson CV, Putrino D, Rydberg L, Silver JK, Terzic CM, Whiteson JH, Niehaus WN. Cheng AL, et al. PM R. 2025 Jun;17(6):684-708. doi: 10.1002/pmrj.13397. Epub 2025 Apr 22. PM R. 2025. PMID: 40261198
  • Management of urinary stones by experts in stone disease (ESD 2025).
    Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, Elhowairis M, Galán-Llopis JA, Geavlete P, Guimerà Garcia J, Isern B, Jinga V, Lopez JM, Mainez JA, Mitsogiannis I, Mora Christian J, Moussa M, Multescu R, Oguz Acar Y, Petkova K, Piñero A, Popov E, Ramos Cebrian M, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A. Papatsoris A, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
  • Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review.
    Thomson K, Rice S, Arisa O, Johnson E, Tanner L, Marshall C, Sotire T, Richmond C, O'Keefe H, Mohammed W, Gosney M, Raffle A, Hanratty B, McEvoy CT, Craig D, Ramsay SE. Thomson K, et al. Health Technol Assess. 2022 Dec;26(51):1-112. doi: 10.3310/CCQF1608. Health Technol Assess. 2022. PMID: 36541454 Free PMC article.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • Citrullinemia Type I.
    Quinonez SC, Lee KN. Quinonez SC, et al. 2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301631 Free Books & Documents. Review.

References

    1. Roediger R., Dieterich D., Chanumolu P., Deshpande P. Polycystic Kidney/Liver Disease. Clin. Liver Dis. 2022;26:229–243. doi: 10.1016/j.cld.2022.01.009. - DOI - PubMed
    1. Torres V.E., Harris P.C., Pirson Y. Autosomal Dominant Polycystic Kidney Disease. Lancet. 2007;369:1287–1301. doi: 10.1016/S0140-6736(07)60601-1. - DOI - PubMed
    1. Zhang Z.-Y., Wang Z.-M., Huang Y. Polycystic Liver Disease: Classification, Diagnosis, Treatment Process, and Clinical Management. World J. Hepatol. 2020;12:72–83. doi: 10.4254/wjh.v12.i3.72. - DOI - PMC - PubMed
    1. Norcia L.F., Watanabe E.M., Filho P.T.H., Hasimoto C.N., Pelafsky L., de Oliveira W.K., Sassaki L.Y. Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment. Hepatic Med. Evid. Res. 2022;14:135–161. doi: 10.2147/HMER.S377530. - DOI - PMC - PubMed
    1. Torres V.E., Ahn C., Barten T.R.M., Brosnahan G., Cadnapaphornchai M.A., Chapman A.B., Gall E.C.-L., Drenth J.P.H., Gansevoort R.T., Harris P.C., et al. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Executive Summary. Kidney Int. 2025;107:234–254. doi: 10.1016/j.kint.2024.07.010. - DOI - PubMed

Supplementary concepts

LinkOut - more resources